Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Drops By 37.3%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,310,000 shares, a decrease of 37.3% from the December 31st total of 2,090,000 shares. Approximately 2.3% of the shares of the stock are sold short. Based on an average trading volume of 6,420,000 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

APTO has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research report on Friday, January 10th. StockNews.com began coverage on shares of Aptose Biosciences in a report on Saturday. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO traded up $0.01 on Friday, hitting $0.18. The company’s stock had a trading volume of 461,077 shares, compared to its average volume of 712,614. The stock has a 50 day moving average of $0.21 and a 200-day moving average of $0.35. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.20. The company has a market capitalization of $10.59 million, a price-to-earnings ratio of -0.06 and a beta of 0.87.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.